Hematopoietic stem cell transplantation for MS: Extraordinary evidence still needed

JAMA - Journal of the American Medical Association

Volumn 313, Issue 3, 2015, Pages 251-252

  Hauser, Stephen L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; GADOLINIUM; GLATIRAMER; INTERFERON; NATALIZUMAB; THYMOCYTE ANTIBODY;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE COURSE; DISEASE FREE SURVIVAL; EDITORIAL; EVIDENCE BASED MEDICINE; EXPANDED DISABILITY STATUS SCALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL LITERATURE; MEMORY CELL; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGRESSION FREE SURVIVAL; PUBLISHING; QUALITY OF LIFE; RECURRENCE FREE SURVIVAL; BRAIN; DISABILITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY;

BRAIN; DISABILITY EVALUATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84921523994     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.18150     Document Type: Editorial

References (11)

1. Hauser SL, Chan JR, Oksenberg JR. Multiple sclerosis: prospects and promise. Ann Neurol. 2013; 74(3):317-327.
2. Atkins HL, Freedman MS. Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned. Neurotherapeutics. 2013;10(1):68-76.
3. Burt RK, Balabanov R, Han X, et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA. doi:10.1001/jama.2014.17986.
4. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy. Lancet. 2012;380(9856):1829-1839.
5. Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73(3):327-340.
6. Bevan CJ, Cree BA. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? JAMA Neurol. 2014;71(3):269-270.
7. Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. doi:10.1001 /jamaneurol.2014.3780.
8. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
9. Abrahamsson SV, Angelini DF, Dubinsky AN, et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain. 2013;136(pt 9):2888-2903.
10. Muraro PA, Robins H, Malhotra S, et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest. 2014;124(3):1168-1172.
11. Palanichamy A, Apeltsin L, Kuo TC, et al. Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Sci Transl Med. 2014;6(248): 248ra106.